Clinical trials: Allogenic Disease
Graft Versus Host Disease, Hematologic Malignancy
Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis
This is a two arm open label phase III clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from any donor are eligible for the study if they meet the standard criteria defined in the…
- Conditions
- Graft Versus Host Disease, Hematologic Malignancy, Cyclophosphamide Adverse Reaction
- Trial name
- CY25 (NCT05158608)
- Testing
- Post-transplantation Cyclophosphamide at dose 25 mg/kg/day, Post-transplantation Cyclophosphamide at dose 50 mg/kg/day
- Volunteers
- 100 people
- Sponsor
- National Research Center for Hematology, Russia
COVID19
Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19
COVID19 pandemic currently represents a public health emergency. Based on current data, 15% of the affected individuals will develop a severe form of the disease requiring admission to hospital and respiratory support.
- Trial name
- (COVID19_BMT) (NCT04349540)
- Testing
- no intervention
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Relapsed Adult AML, Stem Cell Transplant Complications
Menin-Inhibitor Targeted Maintenance in AML
Revumenib is a first in class oral menin inhibitor that targets a central oncogenic dependency shared across KMT2Ar, NPM1m, and NUP98r AML.
- Conditions
- Relapsed Adult AML, Stem Cell Transplant Complications, Acute Myeloid Leukemia, Transplant-Related Hematologic Malignancy
- Trial name
- NCT07563010
- Testing
- Revumenib
- Volunteers
- 146 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Acute Myeloid Leukemia
Mismatched Donor Cells to Treat Acute Myeloid Leukemia
The purpose of this study is to assess the safety and efficacy of infusing immune cells from a donor as treatment for patients with acute myeloid leukemia that is resistant to chemotherapy or who have experienced relapse.
- Trial name
- ATAC-AML-01 (NCT01793025)
- Testing
- ATAC Therapy
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Pneumocystis Pneumonia
A Case-control Study on Risk Factors, Timing, and PCR Use, for Pneumocystis Pneumonia (PcP) After Allogeneic HSCT
The fungus Pneumocystis jirovecii is responsible for pneumocystosis (PcP), a life threatening pneumonia in patients undergoing HSCT.
- Trial name
- NCT05077150
- Where
- 9 sites in Belgium, France and 4 more
- Volunteers
- 168 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation
This is a phase II study of allogeneic hematopoietic progenitor cell transplantation (HPCT) followed reduced toxicity conditioning with once daily intravenous Busulfex and fludarabine in patients with relapsed/chemotherapy…
- Trial name
- NCT01203020
- Testing
- Busulfan, Fludarabine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- West Virginia University
Acute Lymphoblastic Leukemia (ALL) in Complete Remission, Acute Myeloid Leukemia (AML) in Remission
Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients
This randomized clinical trial will evaluate two approaches of GvHD prophylaxis; the standard of care GVHD prophylaxis regimen (methotrexate/calcineurin inhibitors) and post-transplant cyclophosphamide with calcineurin inhibitors…
- Trial name
- PTCy-PMAT (NCT04314219)
- Testing
- Cyclophosphamide 50mg, Methotrexate
- Where
- Saudi Arabia
- Volunteers
- 264 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Type 2 Diabetes
Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes
This study is being conducted to assess the overall safety and tolerability of a single intravenous infusion of three doses of Mesenchymal Precursor Cells versus Placebo in subjects with Type 2 Diabetes inadequately controlled on…
- Trial name
- NCT01576328
- Testing
- Mesenchymal Precursor Cells (MPCs)
- Where
- 18 sites in United States
- Volunteers
- 61 people
- Sponsor
- Mesoblast, Ltd.
Diabetes Mellitus, Diabetes Mellitus, Type 1
An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D
This is an open-label, multicenter, Phase 1 study evaluating the safety and tolerability of VCTX210A combination product in patients with T1D
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- NCT05210530
- Testing
- VCTX210A unit
- Where
- 3 sites in Canada
- Volunteers
- 7 people
- Sponsor
- CRISPR Therapeutics AG
Craniosynostosis, Bleeding
Tranexamic Acid for Craniofacial Surgery
This is a randomized, blinded, prospective study that will investigate the potential benefit of tranexamic acid to reduce the intraoperative bleeding and blood transfusions in pediatric patients undergoing craniofacial surgeries.
- Trial name
- NCT00722436
- Testing
- Tranexamic acid, saline
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pittsburgh
Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation
This randomized placebo-controlled double-blind phase II trial tests whether fecal microorganism (microbiota) transplantation prevents severe acute graft versus host disease in adults undergoing allogeneic hematopoietic cell…
- Trial name
- NCT06026371
- Testing
- Fecal Microbiota Transplantation Capsule
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- Fred Hutchinson Cancer Center
Immune Thrombocytopenia (ITP)
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells(QT-019C) in Patients With Refractory Primary Immune Thrombocytopenia.
- Trial name
- NCT07416032
- Testing
- QT-019C
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hurler Syndrome
Administration of IV Laronidase Post Bone Marrow Transplant in Hurler
This is a single center pilot study in which Laronidase will be given weekly for two years in patients with Hurler syndrome, also known as mucopolysaccharide IH (MPS I, Hurler syndrome), that have previously been treated with an…
- Trial name
- NCT01173016
- Testing
- Laronidase
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Haploidentical Hematopoietic Stem Cell Transplantation, Malignant Disease
Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents
Purpose of study: This phase I/II trial is to evaluate the safety and feasibility of TCRαβ-depleted graft from haploidentical family donors in treating children and adolescents with malignant or non-malignant diseases.
- Conditions
- Haploidentical Hematopoietic Stem Cell Transplantation, Malignant Disease, Non-malignant Disease
- Trial name
- NCT02014506
- Testing
- Fludarabine, Cyclophosphamide, anti-thymocyte globulin
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
Acute-On-Chronic Liver Failure
Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure
This is an interventional, single arm, multicenter, phase I/IIa clinical trial. The study objective is to investigate the efficacy and safety of three i.v.
- Trial name
- NCT03860155
- Testing
- allo-APZ2-ACLF
- Where
- 5 sites in Germany
- Volunteers
- 5 people
- Sponsor
- RHEACELL GmbH & Co. KG
Cardiomyopathy, Heart Failure
Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines
This randomized pilot phase I trial studies the side effects and best method of delivery of bone marrow derived mesenchymal stem cells (MSCs) in improving heart function in patients with heart failure caused by anthracyclines (a…
- Trial name
- NCT02408432
- Testing
- Laboratory Biomarker Analysis, Standard of Care, Mesenchymal Stem Cell Transplantation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Cerebral Palsy
Stem Cell and Conditioned Medium for Cerebral Palsy
The aim of this study was to compare the effectiveness of umbilical cord mesenchymal stem cells (UCMSCs) and conditioned medium (CM) administration, UCMSCs only and control with standard therapy.
- Trial name
- NCT04314687
- Testing
- Umbilical Cord Mesenchymal Stem Cells, Conditioned Medium, Standard Therapy
- Where
- Indonesia
- Volunteers
- 78 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Epstein-Barr Virus Infection, Post-Transplant Lymphoproliferative Disorder
Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
Epstein-Barr virus (EBV) DNAemia is a common and potentially serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and may progress to EBV-associated lymphoproliferative disorders.
- Trial name
- NCT07368634
- Testing
- EBV-TCR-T Cell Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Daihong Liu
Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase
Haploid Allogeneic Transplant Using the CliniMACS System
To assess the proportion of patients with donor neutrophil engraftment within 30 days of allogeneic transplant. To assess the incidence of acute GvHD during the first 100 days after transplantation.
- Conditions
- Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase, Myelodysplastic Syndrome (MDS) - High and Intermediate Risk, Non-Hodgkin's Lymphoma (NHL)
- Trial name
- NCT00185679
- Testing
- CliniMACS System
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Ginna Laport
B-cell Lymphoma, Non-Hodgkin Lymphoma
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.
- Conditions
- B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Trial name
- NCT05643742
- Testing
- CTX112
- Where
- 7 sites in United States, Australia
- Volunteers
- 120 people
- Sponsor
- CRISPR Therapeutics AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.